# A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

Study · id `cardio:ct-nct04714320` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04714320](<https://clinicaltrials.gov/study/NCT04714320>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04714320

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT04714320. Randomized; no masking; primary purpose treatment. Start 2021-04-28 (actual); primary completion 2022-06-29 (actual). Results posted on 2025-02-18.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT04714320, source copy `cardio:ctgov-nct04714320-2025-02-18`, retrieved 2026-10-26)
- Started: 2021-04-28 (actual) (ClinicalTrials.gov record NCT04714320, source copy `cardio:ctgov-nct04714320-2025-02-18`, retrieved 2026-10-26)
- Primary completion: 2022-06-29 (actual) (ClinicalTrials.gov record NCT04714320, source copy `cardio:ctgov-nct04714320-2025-02-18`, retrieved 2026-10-26)
- Completion: 2022-10-03 (actual) (ClinicalTrials.gov record NCT04714320, source copy `cardio:ctgov-nct04714320-2025-02-18`, retrieved 2026-10-26)
- Results first posted: 2025-02-18 (ClinicalTrials.gov record NCT04714320, source copy `cardio:ctgov-nct04714320-2025-02-18`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT04714320, source copy `cardio:ctgov-nct04714320-2025-02-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04714320-2025-02-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
- Acronym: ASTRAAS
- Condition: Hypertension
- Intervention (Drug): Placebo
- Intervention (Drug): IONIS-AGT-LRx
- Lead sponsor: Ionis Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Ionis Pharmaceuticals, Inc. (`cardio:org-ionis-pharmaceuticals-inc`)

## Provenance

Content hash: 65b5de0eab25877ae82cf9bc789d3cb992906f7b538f166ec03937d8ea5aaad2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
